Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial

Nature Medicine, Published online: 04 June 2025; doi:10.1038/s41591-025-03725-4

The final analysis from the phase 3 IMpassion031 trial shows that adding atezolizumab to chemotherapy for stage II/III triple-negative breast cancer is associated with favorable long-term outcomes, with circulating tumor DNA clearance correlating with therapy response.